2021年7月
Development of ciclesonide analogues that block SARS-CoV-2 RNA replication
Bioorganic & Medicinal Chemistry Letters
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 43
- 号
- 開始ページ
- 128052
- 終了ページ
- 128052
- 記述言語
- 英語
- 掲載種別
- 研究論文（学術雑誌）
- DOI
- 10.1016/j.bmcl.2021.128052
- 出版者・発行元
- Elsevier {BV}
Ciclesonide is an inhaled corticosteroid used to treat asthma and is currently undergoing clinical trials for treatment of coronavirus disease 2019 (COVID-19). An active metabolite of ciclesonide, Cic2, was recently reported to repress severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genomic RNA replication. Herein, we designed and synthesized a few types of ciclesonide analogues. Cic4 (bearing an azide group) and Cic6 (bearing a chloro group) potently decreased SARS-CoV-2 viral replication and had low cytotoxicity compared with Cic2 (bearing a hydroxy group). These compounds are promising as novel therapeutic agents for COVID-19 that show significant antiviral activity.
- リンク情報
-
- DOI
- https://doi.org/10.1016/j.bmcl.2021.128052
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/33887440
- PubMed Central
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055493
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000663580200005&DestApp=WOS_CPL
- ID情報
-
- DOI : 10.1016/j.bmcl.2021.128052
- ISSN : 0960-894X
- eISSN : 1464-3405
- ORCIDのPut Code : 92509672
- PubMed ID : 33887440
- PubMed Central 記事ID : PMC8055493
- Web of Science ID : WOS:000663580200005